A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Yu-Wei Chen, Lin Liu, Yuwei Cheng, Arlene Araneta, Neremiah Castano, Jennifer Gomez, Archana Ajmera, Huihui Ye, Karie Runcie, Deaglan Joseph McHugh, Kenneth Offit, Channing Judith Paller, Naomi Balzer Haas, Robert Allison Franklin, Roberto Pili, Juan Javier-Desloges, Christopher J. Kane, Tyler M Seibert, Aditya Bagrodia, Rana R. McKay
Institutions: University of California San Diego Medical Center, University of California San Diego, Cedars-Sinai Medical Center, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Abramson Cancer Center, University of Pennsylvania, University of Cincinnati Medical Center, University at Buffalo, State University of New York, UC San Diego Health System, Moores Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407701116